AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

Funding to North American startups surged in the first half of 2025, fueled by investor enthusiasm around artificial ...

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie ...

The gene editing company has seen its shares surge approximately 160% since mid-June, building on momentum that began after a ...

US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...